After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...